Vivian Barak

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/10938235/publications.pdf

Version: 2024-02-01

315357 279487 2,569 39 23 38 citations h-index g-index papers 40 40 40 3650 all docs docs citations times ranked citing authors

#	Article	IF	CITATIONS
1	Exploring the potential of mucin 13 (MUC13) as a biomarker for carcinomas and other diseases. Clinical Chemistry and Laboratory Medicine, 2018, 56, 1945-1953.	1.4	15
2	The relationship between serum cytokine levels and degree of psychosis in patients with schizophrenia. Psychiatry Research, 2018, 268, 467-472.	1.7	44
3	Optimal Use of Biomarkers in Oncology. BioMed Research International, 2015, 2015, 1-2.	0.9	3
4	Validation of New Cancer Biomarkers: A Position Statement from the European Group on Tumor Markers. Clinical Chemistry, 2015, 61, 809-820.	1.5	120
5	The Diagnostic and Prognostic Value of Tumor Markers (CEA, SCC, CYFRA 21-1, TPS) in Head and Neck Cancer Patients. Anticancer Research, 2015, 35, 5519-24.	0.5	36
6	Vitamin D Inflammatory Cytokines and Coronary Events: A Comprehensive Review. Clinical Reviews in Allergy and Immunology, 2013, 45, 236-247.	2.9	64
7	Design of Tumor Biomarker–Monitoring Trials: A Proposal by the European Group on Tumor Markers. Clinical Chemistry, 2013, 59, 52-59.	1.5	37
8	Serum transforming growth factor beta-1 post hip fracture repair in elderly patients. Cytokine, 2011, 54, 56-60.	1.4	2
9	VEGF as a Biomarker for Metastatic Uveal Melanoma in Humans. Current Eye Research, 2011, 36, 386-390.	0.7	43
10	The dynamics of serum tumor markers in predicting metastatic uveal melanoma (part 1). Anticancer Research, 2011, 31, 345-9.	0.5	21
11	Relevance of circulating biomarkers for the therapy monitoring and follow-up investigations in patients with non-small cell lung cancer. Cancer Biomarkers, 2010, 6, 191-196.	0.8	24
12	Cytokines and C-Reactive Protein Production in Hip-Fracture-Operated Elderly Patients. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2007, 62, 420-426.	1.7	192
13	Using the Direct-Injection Model of Early Uveal Melanoma Hepatic Metastasis to Identify TPS as a Potentially Useful Serum Biomarker. , 2007, 48, 4399.		11
14	Interplay among oxidants, antioxidants, and cytokines in skin disorders: Present status and future considerations. Biomedicine and Pharmacotherapy, 2007, 61, 412-422.	2.5	94
15	Novel Biomarkers in Autoimmune Diseases. Annals of the New York Academy of Sciences, 2007, 1109, 385-400.	1.8	204
16	Serum markers to detect metastatic uveal melanoma. Anticancer Research, 2007, 27, 1897-900.	0.5	48
17	Tumor Markers in Breast Cancer – European Group on Tumor Markers Recommendations. Tumor Biology, 2005, 26, 281-293.	0.8	287
18	Markedly elevated levels of inflammatory cytokines in maternal serum and peritoneal washing during arrested labor. Acta Obstetricia Et Gynecologica Scandinavica, 2004, 83, 358-363.	1.3	10

#	Article	IF	Citations
19	Clinical utility of cytokeratins as tumor markers. Clinical Biochemistry, 2004, 37, 529-540.	0.8	318
20	Interleukin-18 levels correlate with severe ovarian hyperstimulation syndrome. Fertility and Sterility, 2004, 82, 415-420.	0.5	23
21	PADMA-28, a Tibetan herbal preparation is an inhibitor of inflammatory cytokine production. European Cytokine Network, 2004, 15, 203-9.	1.1	24
22	The involvement of IL-6 and IL-8 in acute invasive gastroenteritis of children. Cytokine, 2003, 22, 194-197.	1.4	8
23	Evaluation of urine CYFRA 21-1 for the detection of primary and recurrent bladder carcinoma. Cancer, 2002, 94, 2914-2922.	2.0	71
24	Soluble ICAM-1 and E-selectin levels correlate with clinical and biological aspects of severe ovarian hyperstimulation syndome. Fertility and Sterility, 2001, 76, 51-57.	0.5	19
25	Markedly elevated levels of vascular endothelial growth factor, fibroblast growth factor, and interleukin 6 in Meigs syndrome. American Journal of Obstetrics and Gynecology, 2001, 184, 354-355.	0.7	59
26	Bone marrow stromal dysfunction in mice administered cytosine arabinoside. European Journal of Haematology, 2001, 66, 230-237.	1.1	19
27	Monoclonal anti-endothelial cell antibodies from a patient with Takayasu arteritis activate endothelial cells from large vessels. Arthritis and Rheumatism, 1999, 42, 1421-1432.	6.7	59
28	Activation of Murine Macrophages by Lipoprotein and Lipooligosaccharide of <i>Treponema denticola </i> . Infection and Immunity, 1999, 67, 1180-1186.	1.0	49
29	Ciprofloxacin immunomodulation of experimental antiphospholipid syndrome associated with elevation of interleukin-3 and granulocyte-macrophage colony-stimulating factor expression. Arthritis and Rheumatism, 1998, 41, 224-232.	6.7	50
30	Evaluation of tissue polypeptide specific antigen, CYFRA 21-1, and carcinoembryonic antigen in nonsmall cell lung carcinoma., 1998, 82, 1850-1859.		99
31	Prevalence of Hypophosphatemia in Sepsis and Infection: The Role of Cytokines. American Journal of Medicine, 1998, 104, 40-47.	0.6	152
32	Cytokeratin Markers in Malignant Pleural Mesothelioma. Cancer Detection and Prevention, 1998, 22, 416-421.	2.1	10
33	Vascular endothelial growth factor plasma levels correlate to the clinical picture in severe ovarian hyperstimulation syndrome. Fertility and Sterility, 1997, 67, 261-265.	0.5	169
34	Human Monocyte Response to Cementum Extracts From Periodontally Diseased Teeth: Effect of Conditioning With Tetracycline. Journal of Periodontology, 1996, 67, 682-687.	1.7	11
35	Defective in Vitro Granulopoiesis in Patients with Anorexia Nervosa. Pediatric Research, 1996, 40, 108-111.	1.1	28
36	Changes in Interleukin- 1^2 and Soluble Interleukin-2 Receptor Levels in CSF and Serum of Schizophrenic Patients. Journal of Basic and Clinical Physiology and Pharmacology, 1995, 6, 61-9.	0.7	94

#	Article	IF	CITATIONS
37	In vivo anti inflammatory effects of the M20 IL-1 Inhibitor: I. Effects on acute inflammatory parameters. Biotherapy (Dordrecht, Netherlands), 1993, 6, 263-270.	0.7	4
38	In vivo anti-inflammatory effects of the M20 IL-1 Inhibitor: II. Effects on serum reactants. Biotherapy (Dordrecht, Netherlands), 1993, 6, 271-277.	0.7	5
39	Serum Soluble Interleukin-2 Receptor Levels are Associated with Clinical Disease Status and Histopathological Grade in Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia. Leukemia and Lymphoma, 1992, 7, 431-438.	0.6	40